Provigil and Levothyroxine Interaction: What Prescribers and Patients Should Know

Modafinil (brand name Provigil), a wakefulness-promoting agent FDA-approved for narcolepsy, obstructive sleep apnea-related sleepiness, and shift work disorder, and levothyroxine (brand names Synthroid, Levoxyl, Tirosint, and others), the standard synthetic T4 replacement for hypothyroidism, are not a contraindicated combination. The interaction that matters here is not acute and not dangerous in the way an overdose or a QT-prolonging combination would be. It is a slow, enzyme-mediated drift in thyroid hormone clearance that shows up weeks later as a TSH change, not as a same-day symptom.

The core answer: Modafinil is labeled by the FDA as a moderate inducer of hepatic CYP3A4. Because thyroid hormone clearance depends partly on hepatic phase I and phase II metabolism, sustained modafinil use is pharmacologically plausible as a driver of increased levothyroxine clearance over several weeks, which could push TSH upward in a levothyroxine-treated patient. This mechanism is distinct from, and often confused with, the well-established levothyroxine absorption interaction caused by food, coffee, calcium, and iron taken too close to the levothyroxine dose. The FDA-approved Provigil and Synthroid labels support each half of that distinction separately; no controlled trial specifically measuring modafinil's effect on levothyroxine pharmacokinetics or TSH was located for this review, so the magnitude and reliability of any TSH shift in real patients remains unverified.

What is established, what is plausible, and what is not proven

The most useful thing this page can do is separate three tiers of confidence, because most existing interaction summaries blend them into one flat "monitor TSH" instruction without saying why.

Evidence-status assessment for the modafinil-levothyroxine pairing

How the two mechanisms differ, and why that matters for timing advice

Two separate interaction pathways get lumped together in casual interaction checkers, and they call for different fixes.

The first is absorption competition. Levothyroxine has a narrow therapeutic index and its labeled instructions call for dosing on an empty stomach, roughly 30 to 60 minutes before food, coffee, or other medications, per the Synthroid label. Modafinil itself does not chemically bind T4 or meaningfully change gastric pH. The practical risk is behavioral: patients often take modafinil at the same time as breakfast, coffee, or morning supplements, and those co-administered substances (not the modafinil) are what blunts levothyroxine absorption. Separating levothyroxine from breakfast, coffee, calcium, and iron by 30 to 60 minutes addresses this pathway regardless of whether modafinil is in the mix at all.

The second is hepatic enzyme induction, which is slower, dose-dependent, and unrelated to timing on any given day. If it occurs, it develops over the weeks it takes CYP3A4 induction to reach a new steady state, and it resolves over a similar timescale after modafinil is stopped. No amount of dose-spacing changes this pathway; only a levothyroxine dose adjustment based on a follow-up TSH does.

Conflating the two leads to the common but imprecise instruction to "just separate the doses and you're fine." Separating the doses fixes the absorption pathway. It does not address a possible induction-driven clearance increase, which requires a TSH recheck instead.

A reasonable monitoring approach

Given the mechanism described in the FDA label and the general guideline-level teaching on enzyme inducers as a class, a cautious and clinically conventional approach looks like this. This is site judgment built from the mechanism and general endocrine monitoring practice, not a validated modafinil-specific protocol, and prescribers should apply their own clinical judgment and local guidance.

When modafinil is added to an existing levothyroxine regimen:

1. Note the most recent TSH, or obtain one within a few weeks of starting modafinil if the last value is old.
2. Recheck TSH roughly 6 to 8 weeks after modafinil initiation, allowing time for enzyme induction to approach steady state.
3. If TSH has moved outside the patient's target range, adjust the levothyroxine dose using standard incremental steps and recheck again after the next dosing interval, following the same approach used for any other enzyme-inducing medication.
4. If TSH is unchanged, no adjustment is needed; resume routine monitoring.

When modafinil is discontinued:

1. Recognize that de-induction unwinds over a comparable timescale, and that a levothyroxine dose raised while on modafinil may become too high once modafinil is stopped.
2. Recheck TSH roughly 6 to 8 weeks after discontinuation and reduce the levothyroxine dose if TSH has dropped below target.

There is no published data specific to this drug pair establishing exactly what fraction of patients need an adjustment or by how much. Any number offered for "typical dose change" in secondary sources should be treated as unverified until checked against a primary study.

Who needs closer attention

Two groups deserve more careful surveillance than a typical hypothyroid patient on a stable dose.

Thyroid cancer survivors on TSH-suppression therapy are managed with a narrow target range, often below 0.5 mIU/L, per American Thyroid Association thyroid cancer management guidelines. Because their margin for error is small, even a modest clearance change could move TSH out of the suppression window. These patients warrant a TSH recheck any time modafinil is started or stopped, regardless of how mild the theoretical interaction is expected to be.

Patients also taking other narrow-therapeutic-index CYP3A4 substrates, such as certain immunosuppressants or hormonal contraceptives, may need coordinated monitoring beyond thyroid labs alone, since modafinil's CYP3A4 induction is not specific to thyroid hormone metabolism. The Provigil label separately warns that modafinil can reduce the effectiveness of steroidal contraceptives, which is a distinct and better-documented labeled interaction that should be addressed on its own terms.

Pregnancy raises levothyroxine requirements substantially through unrelated mechanisms (rising thyroxine-binding globulin, placental effects). Modafinil is generally avoided in pregnancy by sleep specialists, so the two effects stacking is an uncommon clinical scenario in practice, but if it arises it warrants close endocrinology involvement.

The reverse direction: could thyroid status explain a "modafinil isn't working" complaint

Hypothyroidism itself causes fatigue and cognitive slowing that can look identical to modafinil under-response. This is a well-established, general endocrinology observation, not something specific to modafinil. Before increasing a modafinil dose in a patient who reports inadequate benefit, checking TSH is a reasonable first step, since correcting an undertreated thyroid condition may resolve the sleepiness without any change to modafinil dosing at all.

What patients should actually do

Take levothyroxine first thing, with water only, and wait at least 30 to 60 minutes before modafinil, food, coffee, calcium, or iron. This single habit removes the absorption-interaction variable entirely. It does not need to be repeated differently because modafinil happens to be part of the morning routine; the same spacing advice applies to anything taken at breakfast.

Ask your prescriber about a TSH recheck 6 to 8 weeks after starting or stopping modafinil, particularly if you are on a narrow TSH target (such as after thyroid cancer treatment) or you notice new fatigue, cold intolerance, constipation, weight gain, or dry skin during that window. These symptoms are easy to misattribute to modafinil itself when the actual issue is a shift in thyroid status.

If you experience acute symptoms such as chest pain, palpitations, severe agitation, or signs of thyroid storm (high fever, rapid heart rate, confusion), this is not something to monitor at home. Seek urgent care.

Bottom line

The modafinil-levothyroxine pairing is safe to use together and is not flagged as contraindicated by the FDA label or by standard interaction references. The realistic concern is a slow, mechanistically plausible increase in levothyroxine clearance from CYP3A4 induction, which is separate from the well-established absorption interaction caused by food and supplements taken too close to the levothyroxine dose. No modafinil-specific clinical trial quantifying the TSH effect was identified for this review. Until such data exists, the sound approach is dose-timing separation for the absorption pathway plus an empirical TSH recheck 6 to 8 weeks after starting or stopping modafinil for the induction pathway, with adjustments made from the patient's own lab result rather than from a generic percentage.